196 related articles for article (PubMed ID: 33467394)
1. Mortality of Pandrug-Resistant
Papadimitriou-Olivgeris M; Bartzavali C; Georgakopoulou A; Kolonitsiou F; Papamichail C; Spiliopoulou I; Christofidou M; Fligou F; Marangos M
Antibiotics (Basel); 2021 Jan; 10(1):. PubMed ID: 33467394
[TBL] [Abstract][Full Text] [Related]
2. Carbapenemase-producing Klebsiella pneumoniae bloodstream infection in critically ill patients: risk factors and predictors of mortality.
Papadimitriou-Olivgeris M; Fligou F; Bartzavali C; Zotou A; Spyropoulou A; Koutsileou K; Vamvakopoulou S; Sioulas N; Karamouzos V; Anastassiou ED; Spiliopoulou I; Christofidou M; Marangos M
Eur J Clin Microbiol Infect Dis; 2017 Jul; 36(7):1125-1131. PubMed ID: 28102514
[TBL] [Abstract][Full Text] [Related]
3. Impact of Tigecycline's MIC in the Outcome of Critically Ill Patients with Carbapenemase-Producing
Papadimitriou-Olivgeris M; Bartzavali C; Nikolopoulou A; Kolonitsiou F; Mplani V; Spiliopoulou I; Christofidou M; Fligou F; Marangos M
Antibiotics (Basel); 2020 Nov; 9(11):. PubMed ID: 33228012
[TBL] [Abstract][Full Text] [Related]
4. External validation of INCREMENT-CPE score in a retrospective cohort of carbapenemase-producing Klebsiella pneumoniae bloodstream infections in critically ill patients.
Papadimitriou-Olivgeris M; Bartzavali C; Georgakopoulou A; Kolonitsiou F; Mplani V; Spiliopoulou I; Christofidou M; Fligou F; Marangos M
Clin Microbiol Infect; 2021 Jun; 27(6):915.e1-915.e3. PubMed ID: 33444757
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for infection and predictors of mortality among patients with KPC-producing Klebsiella pneumoniae bloodstream infections in the intensive care unit.
Papadimitriou-Olivgeris M; Marangos M; Christofidou M; Fligou F; Bartzavali C; Panteli ES; Vamvakopoulou S; Filos KS; Anastassiou ED
Scand J Infect Dis; 2014 Sep; 46(9):642-8. PubMed ID: 25017796
[TBL] [Abstract][Full Text] [Related]
6. Reversal of carbapenemase-producing Klebsiella pneumoniae epidemiology from blaKPC- to blaVIM-harbouring isolates in a Greek ICU after introduction of ceftazidime/avibactam.
Papadimitriou-Olivgeris M; Bartzavali C; Lambropoulou A; Solomou A; Tsiata E; Anastassiou ED; Fligou F; Marangos M; Spiliopoulou I; Christofidou M
J Antimicrob Chemother; 2019 Jul; 74(7):2051-2054. PubMed ID: 31002313
[TBL] [Abstract][Full Text] [Related]
7. Characterization of Extensively Drug-Resistant or Pandrug-Resistant Sequence Type 147 and 101 OXA-48-Producing Klebsiella pneumoniae Causing Bloodstream Infections in Patients in an Intensive Care Unit.
Avgoulea K; Di Pilato V; Zarkotou O; Sennati S; Politi L; Cannatelli A; Themeli-Digalaki K; Giani T; Tsakris A; Rossolini GM; Pournaras S
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29661874
[TBL] [Abstract][Full Text] [Related]
8. Molecular epidemiology and risk factors for colistin- or tigecycline-resistant carbapenemase-producing Klebsiella pneumoniae bloodstream infection in critically ill patients during a 7-year period.
Papadimitriou-Olivgeris M; Bartzavali C; Spyropoulou A; Lambropoulou A; Sioulas N; Vamvakopoulou S; Karpetas G; Spiliopoulou I; Vrettos T; Anastassiou ED; Fligou F; Christofidou M; Marangos M
Diagn Microbiol Infect Dis; 2018 Nov; 92(3):235-240. PubMed ID: 30076041
[TBL] [Abstract][Full Text] [Related]
9. Synergistic activity of fosfomycin-meropenem and fosfomycin-colistin against carbapenem resistant
Bakthavatchalam YD; Shankar A; Muthuirulandi Sethuvel DP; Asokan K; Kanthan K; Veeraraghavan B
Future Sci OA; 2020 Feb; 6(4):FSO461. PubMed ID: 32257374
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Septic Shock Due to Multidrug-Resistant Acinetobacter baumannii or Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae in Intensive Care Unit Patients.
Russo A; Giuliano S; Ceccarelli G; Alessandri F; Giordano A; Brunetti G; Venditti M
Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29555630
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria.
Pontikis K; Karaiskos I; Bastani S; Dimopoulos G; Kalogirou M; Katsiari M; Oikonomou A; Poulakou G; Roilides E; Giamarellou H
Int J Antimicrob Agents; 2014 Jan; 43(1):52-9. PubMed ID: 24183799
[TBL] [Abstract][Full Text] [Related]
12. Predictors of outcome in ICU patients with septic shock caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae.
Falcone M; Russo A; Iacovelli A; Restuccia G; Ceccarelli G; Giordano A; Farcomeni A; Morelli A; Venditti M
Clin Microbiol Infect; 2016 May; 22(5):444-50. PubMed ID: 26850826
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by Klebsiella pneumoniae Carbapenemase-producing K. pneumoniae.
Tumbarello M; Trecarichi EM; Corona A; De Rosa FG; Bassetti M; Mussini C; Menichetti F; Viscoli C; Campoli C; Venditti M; De Gasperi A; Mularoni A; Tascini C; Parruti G; Pallotto C; Sica S; Concia E; Cultrera R; De Pascale G; Capone A; Antinori S; Corcione S; Righi E; Losito AR; Digaetano M; Amadori F; Giacobbe DR; Ceccarelli G; Mazza E; Raffaelli F; Spanu T; Cauda R; Viale P
Clin Infect Dis; 2019 Jan; 68(3):355-364. PubMed ID: 29893802
[TBL] [Abstract][Full Text] [Related]
14. Changing Characteristics and
Mavroidi A; Katsiari M; Likousi S; Palla E; Roussou Z; Nikolaou C; Mathas C; Merkouri E; Platsouka ED
Microb Drug Resist; 2020 Jan; 26(1):28-37. PubMed ID: 31386596
[TBL] [Abstract][Full Text] [Related]
15. Bloodstream infection caused by KPC-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam: epidemiology and genomic characterization.
Gaibani P; Re MC; Campoli C; Viale PL; Ambretti S
Clin Microbiol Infect; 2020 Apr; 26(4):516.e1-516.e4. PubMed ID: 31740422
[TBL] [Abstract][Full Text] [Related]
16. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study.
Tumbarello M; Trecarichi EM; De Rosa FG; Giannella M; Giacobbe DR; Bassetti M; Losito AR; Bartoletti M; Del Bono V; Corcione S; Maiuro G; Tedeschi S; Celani L; Cardellino CS; Spanu T; Marchese A; Ambretti S; Cauda R; Viscoli C; Viale P;
J Antimicrob Chemother; 2015 Jul; 70(7):2133-43. PubMed ID: 25900159
[TBL] [Abstract][Full Text] [Related]
17. Effect of ceftazidime/avibactam plus fosfomycin combination on 30 day mortality in patients with bloodstream infections caused by KPC-producing
Oliva A; Volpicelli L; Di Bari S; Curtolo A; Borrazzo C; Cogliati Dezza F; Cona A; Agrenzano S; Mularoni A; Trancassini M; Mengoni F; Stefani S; Raponi G; Venditti M
JAC Antimicrob Resist; 2022 Dec; 4(6):dlac121. PubMed ID: 36506890
[TBL] [Abstract][Full Text] [Related]
18. Risk factors and predictors of carbapenem-resistant
Papadimitriou-Olivgeris M; Fligou F; Spiliopoulou A; Koutsileou K; Kolonitsiou F; Spyropoulou A; Zotou A; Marangos M; Anastassiou ED; Christofidou M; Spiliopoulou I
J Med Microbiol; 2017 Aug; 66(8):1092-1101. PubMed ID: 28758623
[No Abstract] [Full Text] [Related]
19. In vitro activity and post-antibiotic effects of colistin in combination with other antimicrobials against colistin-resistant KPC-producing Klebsiella pneumoniae bloodstream isolates.
Gaibani P; Lombardo D; Lewis RE; Mercuri M; Bonora S; Landini MP; Ambretti S
J Antimicrob Chemother; 2014 Jul; 69(7):1856-65. PubMed ID: 24648503
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing
Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F
Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
